Skip to main content
Premium Trial:

Request an Annual Quote

New York Genome Center Gets NYS OK for Clinical Whole Genome Sequencing Test

NEW YORK (GenomeWeb) – The New York Genome Center said today that it has received conditional approval from the New York State Department of Health to offer a clinical constitutional whole-genome sequencing test.

The test will be run in NYGC's clinical laboratory, which is certified under New York State's Clinical Laboratory Evaluation Program (CLEP), and will use the center's Illumina's HiSeq X sequencing platform.

"This whole-genome sequencing service will enable unbiased genetic testing information for patients, and will significantly improve the odds of identifying disease-associated variants that could provide important information pertinent to the patient's disease," Vaidehi Jobanputra, NYGC's director of molecular diagnostics and head of its clinical laboratory, said in a statement.

Doctors can order the test for patients with undiagnosed diseases as well as for ostensibly healthy individuals wishing to undergo disease predisposition testing. For the latter, the test will report secondary findings in the American College of Medical Genetics and Genomics 56-gene list, carrier status for severe pediatric diseases, and variants in pharmacogenomics-relevant genes.

“Whole-genome sequencing will increasingly be utilized as the first-tier molecular test for patients with undiagnosed disease,” said NYS Health Commissioner Howard Zucker in a statement.  “The next-generation, advanced sequencing technology used by the New York Genome Center increases the efficiency and scalability of whole-genome sequence testing, which will benefit New York State physicians and their patients.”

NYGC said it is also seeking New York State approval for whole genome sequencing and transcriptome sequencing tests for cancer. Last year, the center obtained approval for an exome sequencing test for patients with undiagnosed disease.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.